beta
/Chengda Pharmaceutical: 2025 Independent Director Work Report (Cui Sunliang)
NEWS

Chengda Pharmaceutical: 2025 Independent Director Work Report (Cui Sunliang)

Shenzhen Stock Exchange
2026/04/28

Chengda Pharmaceutical Co., Ltd.

2025 Independent Directors’ Work Report

(Cui Sunliang)

As an independent director of the fifth board of directors of Chengda Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company"), I will strictly comply with the "Company Law of the People's Republic of China" and "Measures for the Administration of Independent Directors of Listed Companies" in 2025 "Shenzhen Stock Exchange Listed Companies Self-Regulation Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other relevant laws and regulations, as well as the "Articles of Association of Chengda Pharmaceutical Co., Ltd.", "Chengda Pharmaceutical Co., Ltd. Independent Director Work System" and other company-related regulations and requirements, perform duties cautiously, conscientiously, diligently and independently, actively attend relevant meetings, and safeguard the overall interests of the company and the legitimate rights and interests of all shareholders. Since my term of office has expired for 6 years, I resigned after the company held the 2025 second extraordinary general meeting of shareholders on November 12, 2025 to elect a new independent director. After my resignation, I will no longer hold any position in the company. I hereby report my performance of my duties during my term of office in 2025 as follows:

1. Basic information of independent directors

Cui Sunliang, born in 1982, Chinese nationality, no permanent residence abroad, doctoral degree. He once served as a postdoctoral fellow at Colorado State University, a postdoctoral fellow at the University of South Florida, a distinguished researcher at the School of Pharmacy at Zhejiang University, a supervisor of Hangzhou Indole Pharmaceutical Technology Co., Ltd., and an independent director of the company; he is currently a professor at the School of Pharmacy at Zhejiang University and an independent director at Zhejiang East Asia Pharmaceutical Co., Ltd.

As an independent director of the company, after self-examination, I have found that I comply with the relevant requirements for the independence of independent directors in relevant laws and regulations such as the "Measures for the Administration of Independent Directors of Listed Companies", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies", and there is no situation that affects independence.

2. Annual performance of independent directors’ duties

(1) Attendance at meetings

  1. In 2025, the company's fifth board of directors held a total of 3 meetings. I attended the meetings seriously and voted. I had no objection to all the proposals reviewed and approved by the board of directors and voted in agreement.

  2. In 2025, as an independent director of the company’s fifth board of directors, I attended a total of 3 shareholders’ meetings.

In 2025, the convening of the company's board of directors and shareholders' meeting complied with legal procedures, and major business decision-making matters and other major matters all fulfilled relevant procedures and were legal and effective. In line with the principle of prudence and objectivity, I carefully review the meeting proposals and relevant background information with a diligent and responsible attitude, actively participate in the discussion of each proposal, fully express reasonable opinions and suggestions, and exercise my voting rights with a cautious attitude.

(2) Attendance at special committees of the board of directors and special meetings of independent directors

During my term of office in 2025, I serve as the convener of the Nomination Committee of the fifth session of the Board of Directors and the chairman of the fifth session of the Board of Directors.

A member of the Strategy Committee of the Board of Directors and a member of the Audit Committee of the fifth session of the Board of Directors, giving full play to his professional functions

The role of the company is to review matters belonging to the respective fields and provide suggestions and suggestions, thereby improving the standardization of the company's operations.

Play an important role in making correct decisions for the company's board of directors.

In 2025, I participated in special committees 6 times and reviewed and approved 16 proposals, the details of which are as follows:

Serial number Meeting name Time of meeting Proposals considered and passed

  1. "Proposal on the "2024 Internal Audit Work Report" Audit of the Fifth Board of Directors

March 2025 Case";

1 Committee 2025 No.

27th 2. Meeting on the "2025 Internal Audit Work Plan"

Case".

  1. "Proposal on the <2024 Annual Report> and its Summary";

  2. "Proposal on the <2024 Financial Final Account Report>";

  3. "Discussion on the "2024 Internal Control Evaluation Report"

case";

Audit of the Fifth Board of Directors 4. "About the Deposit and Use of Funds Raised in 2024 April 2025

2 Proposal for the Committee’s 2025 Special Report>;

21st

Second meeting 5. "Proposal on Re-appointment of Accounting Firm";

  1. "About the Audit Committee of the Board of Directors on the Accounting Firm

Duty performance evaluation and supervision responsibilities report in 2024

"Proposal";

  1. "Proposal on the "First Quarter Report of 2025".

  2. "Discussion on the 2025 Semi-annual Report" and its Summary

case";

Audit of the fifth board of directors

August 2025 2. "About the Deposit and Use of Funds Raised in the Half Year of 2025" 3 Committee's 2025 Issue

Proposal on the Special Report on the Situation on the 19th;

three meetings

  1. "Discussion on the 2025 Semi-annual Internal Audit Report"

Case".

Audit of the fifth board of directors

October 2025

4 Committee 2025 No. 1. "Proposal on the <Third Quarter Report of 2025>". 21st

four meetings

  1. "Proposal on the General Election of the Company's Board of Directors and Nomination of Non-Independent Director Candidates for the Sixth Board of Directors";

1.01 Nominated Ms. Ge Jianli as a non-independent director candidate for the sixth session of the Board of Directors

1.02 Nominate Mr. Lu Gang as a non-independent director candidate for the sixth session of the Board of Directors

1.03 Nominated Mr. Huang Honglin as a non-independent director candidate for the sixth session of the Board of Directors

1.04 Nominated Ms. Lu Jin as a non-independent director of the sixth board of directors and nominated for the fifth board of directors

October 2025 Candidates

5 Committee 2025 No.

On the 21st, 1.05, Ms. Li Wenjuan was nominated as a non-independent director of the sixth session of the Board of Directors.

candidate

  1. "Proposal on the General Election of the Company's Board of Directors and Nomination of Independent Director Candidates for the Sixth Board of Directors".

2.01 Nominated Mr. Hu Yongzhou as an independent director candidate for the sixth session of the Board of Directors

2.02 Nominate Mr. Jiang Lin as an independent director candidate for the sixth session of the Board of Directors

2.03 Nominate Mr. Zhou Junming as an independent director candidate for the sixth session of the Board of Directors

Strategy of the 5th Board of Directors

April 2025 1. "About the Company's Development Strategy and 2025 Business Plan 6 Committee's 2025 No.

Proposal on the 21st.

a meeting

During the period of performance of duties, the company did not hold a special meeting of independent directors.

(3) Communication with internal audit institutions and accounting firms

In 2025, as an independent director of the fifth session of the board of directors of the company, during the preparation and disclosure process of the company's regular reports, I kept abreast of and mastered the work arrangements of each periodic report, actively followed up on the progress of the annual report audit, exchanged opinions with the annual audit accountants on the preliminary audit results, and promptly discussed with the company's management on key issues in the company's operations to ensure that the audit report fully reflects the true situation of the company; at the same time, during the review of the periodic reports, I was able to fulfill my confidentiality obligations and strictly prevent the leakage of inside information, insider trading and other illegal activities.

(4) On-site work conditions

Due to the general election of the company's board of directors, my position as director of the fifth board of directors will expire on November 12, 2025. In 2025, my cumulative on-site working time is 13 working days. I make full use of participation in special committee meetings of the board of directors, board of directors, shareholders' meetings, etc. to gain an in-depth understanding of the company's production and operation, the improvement and implementation of internal control systems, the implementation of board resolutions, financial management, use of raised funds, business development and other related matters. Through company visits, base research and communication with other directors, senior managers and relevant staff of the company, we can learn about the company's operating status and standardized operations.

(5) The company’s cooperation with independent directors

During the period of performance of duties, the company conscientiously organized relevant meetings, timely delivered documents and materials and reported on the company's relevant operating conditions, providing necessary working conditions for independent directors to perform their duties, and there was no situation that hindered independent directors from performing their duties.

(6) Work done to protect investors’ rights and interests

  1. In 2025, I effectively performed my duties as an independent director. For every proposal submitted to the board of directors for review, I took a serious, diligent and cautious attitude, carefully reviewed relevant documents and information, communicated and contacted with relevant personnel, exercised my voting rights independently, objectively, fairly and prudently, promoted the scientificity and objectivity of the board of directors' decision-making, and effectively safeguarded the legitimate rights and interests of the company and shareholders.

  2. In terms of corporate governance and information disclosure, I continue to pay attention to the company's information disclosure work, actively promote and improve the company's internal control system, and urge the company to strictly comply with the requirements of the "Shenzhen Stock Exchange GEM Stock Listing Rules" and other laws and regulations to improve the company's information disclosure management system; require the company to strictly implement the relevant regulations on information disclosure, ensure that the company's information disclosure is true, accurate, complete, timely and fair, promote the company's standardized operations, and effectively safeguard the legitimate rights and interests of the company and shareholders.

  3. As an independent director of the company, I have always focused on protecting the legitimate rights and interests of shareholders, especially the rights and interests of small and medium-sized shareholders. I have always attached great importance to communication with small and medium-sized shareholders. I have dialogues with investors, listen to suggestions and answer questions through shareholders' meetings, performance briefings, etc.

3. Matters of focus in annual performance of duties

(1) Related transactions that should be disclosed

During his tenure in 2025, the company did not have major related transactions. The decision-making procedures for daily operating related transactions did not violate relevant laws, regulations and the provisions of the Articles of Association. Pricing was based on the principles of equivalent compensation and fair market value. It did not violate the principles of openness, fairness and impartiality, and did not harm the interests of the company and small and medium-sized shareholders.

(2) Disclosure of financial information and internal control evaluation reports in financial accounting reports and periodic reports

In strict accordance with the requirements of relevant laws and regulations such as the "Shenzhen Stock Exchange GEM Stock Listing Rules" and "Shenzhen Stock Exchange Listed Companies Self-Regulatory Guidelines No. 2 - Standardized Operation of GEM Listed Companies" and other relevant laws and regulations, the company prepared and disclosed regular reports and the "2024 Internal Control Evaluation Report" on time, accurately disclosed the financial data and important matters during the corresponding reporting period, and fully disclosed the company's operating conditions and the company's internal control operations to investors. The above-mentioned reports have all fulfilled corresponding review procedures, and the convening procedures, voting procedures and methods of relevant meetings comply with the provisions of relevant laws, regulations and normative documents.

(3) Appointment and dismissal of accounting firms that undertake the audit business of listed companies

The company held the twelfth meeting of the fifth board of directors on April 23, 2025, and reviewed and approved the "Proposal on Re-appointment of the Accounting Firm" and agreed to re-appoint Zhonghua Accounting Firm (Special General Partnership) as the company's financial audit agency and internal control audit agency for 2025.

(4) Nominate or appoint or remove directors, hire or dismiss senior managers

The company held the 14th meeting of the fifth board of directors on October 24, 2025, and reviewed and approved the "Proposal on the General Election of the Company's Board of Directors and Nomination of Non-Independent Director Candidates for the Sixth Board of Directors", "Proposal on the General Election of the Company's Board of Directors and Nomination of Independent Director Candidates for the Sixth Board of Directors", agreed to nominate Ms. Ge Jianli, Mr. Lu Gang, Mr. Huang Honglin, Ms. Lu Jin, and Ms. Li Wenjuan as non-independent director candidates for the sixth session of the Board of Directors, and agreed to nominate three persons, Mr. Hu Yongzhou, Mr. Jiang Lin, and Mr. Zhou Junming, as candidates for independent directors of the sixth session of the Board of Directors. The above-mentioned persons have the qualifications suitable for the exercise of their powers, and their qualifications and appointment procedures comply with the provisions of the "Company Law of the People's Republic of China", "Shenzhen Stock Exchange Self-Regulatory Guidelines for Listed Companies No. 2 - Standardized Operation of GEM Listed Companies" and the "Articles of Association".

4. Other work conditions

  1. During the period of performance of duties, there was no proposal to convene a board of directors or a proposal to the board of directors to convene an extraordinary shareholders' meeting;

  2. During the period of performance of duties, there is no proposal to change or dismiss the accounting firm;

  3. During the period of performance of duties, there is no independent intermediary agency hired to audit, consult or verify specific matters of the company;

5. Overall evaluation and suggestions

In 2025, as an independent director of the company's fifth board of directors, I actively performed my duties and effectively safeguarded the overall interests of the company and the interests of all shareholders.

I would like to express my heartfelt thanks to the company's board of directors, management and relevant personnel for their active and effective cooperation and support during my performance of duties in 2025!

Hereby report! (This page has no text, but is the signature page of the "2025 Independent Directors' Work Report of Chengda Pharmaceutical Co., Ltd.")

Independent Director:_____________

Cui Sunliang

April 24, 2026